Tag Archives: patents

Wyeth v. Abbott Labs. – Picking Plaintiff’s Poison

Posted on June 28, 2013 by Warren Woessner

In July of 2011, I wrote a post for this blog on BSC v. J&J, a Fed. Cir. decision in which four J&J patents claiming stents eluting rapamycin, a drug that inhibits restenosis after balloon angioplasty, were held invalid for … Continue reading →

Posted in Enablement, Written Description Requirements (WDR) | Tagged , , , , , , , , , , | 1 Comment

Finally, A Reasonable Decision

Posted on June 24, 2013 by Warren Woessner

This is a guest post from Greg Stark, attorney at Schwegman Lundberg & Woessner. Attached at the end of this post is an annotated copy of the June 21st decision from the Federal Circuit in Ultramercial v. Hulu. The underlying patent … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Association For Molecular Pathology V Myriad Genetics – An Isolated Local Difficulty?

Posted on June 14, 2013 by Warren Woessner

Paul Cole, Professor of Intellectual Property Law at Bournemouth University and European Patent Attorney at Lucas & Co, Warlingham, Surrey, UK discusses yesterdays Myriad ruling by the Supreme Court. How does yesterday’s Supreme Court decision match international opinion on the patentability … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

CLS Bank International v. Alice Corporation: Poison Apple

Posted on May 24, 2013 by Warren Woessner

This is a guest post from Ron Schutz of Robins, Kaplan, Miller & Ciresi. Move over Snow White.  A deeply-divided Federal Circuit in CLS Bank Int’l.  v. Alice Corp. Pty. Ltd., issued a per curiam opinion that dwarfs the scope … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | Leave a comment